However, the reason why blood GFAP showed a stronger association with Aβ pathology is still unclear; thus, further work is still needed to investigate the mechanisms of GFAP release into the bloodstream under pathological conditions and clarify the key pathological substrates of the better separation of serum/plasma versus CSF in AD (Hansson et al., 2022). This evidence concerns the gene GFAP and Alzheimer disease.